Santhera reconfirms cash flow breakeven target as AGAMREE revenues near-double

The Swiss rare disease specialist expects to reach breakeven in the third quarter of 2026 without raising additional funds. Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0), the Swiss specialty pharma group listed on the SIX Swiss Exchange, has reconfirmed it expects to reach cash flow breakeven during the third quarter of 2026, requiring no additional fundraising, as its Duchenne muscular dystrophy (DMD) drug AGAMREE delivered revenues well ahead of guidance.